TriSalus Life Sciences (NASDAQ:TLSI) Shares Down 4.6% - What's Next?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report)'s stock price traded down 4.6% on Tuesday . The company traded as low as $4.18 and last traded at $4.34. 72,578 shares were traded during mid-day trading, an increase of 100% from the average session volume of 36,327 shares. The stock had previously closed at $4.55.

TriSalus Life Sciences Stock Performance

The company's 50-day moving average price is $5.14 and its 200 day moving average price is $5.29. The stock has a market cap of $167.63 million, a PE ratio of -3.96 and a beta of 0.50.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The firm had revenue of $9.17 million during the quarter, compared to analyst estimates of $9.04 million. During the same period last year, the business posted ($0.60) EPS. On average, sell-side analysts anticipate that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

Insider Transactions at TriSalus Life Sciences

In related news, insider Richard Marshak sold 6,597 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the transaction, the insider directly owned 69,101 shares of the company's stock, valued at approximately $357,943.18. This represents a 8.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 16,125 shares of company stock valued at $83,528 over the last three months. Insiders own 27.50% of the company's stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in shares of TriSalus Life Sciences by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock valued at $1,023,000 after purchasing an additional 3,710 shares during the period. Renaissance Technologies LLC acquired a new position in TriSalus Life Sciences in the fourth quarter valued at $67,000. Northern Trust Corp increased its stake in TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after acquiring an additional 5,936 shares during the last quarter. Bank of America Corp DE boosted its position in shares of TriSalus Life Sciences by 120,471.6% in the fourth quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock worth $894,000 after buying an additional 178,298 shares during the period. Finally, Bridgeway Capital Management LLC boosted its holdings in TriSalus Life Sciences by 333.3% in the fourth quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company's stock valued at $326,000 after purchasing an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 2.58% of the company's stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.